Ionis CSO Frank Bennett to Retire in February 2027 — Ionis Pharmaceuticals, Inc.

Event summary

Frank Bennett, Ph.D., executive vice president and chief scientific officer of Ionis Pharmaceuticals, will retire effective February 2027.
Bennett joined Ionis as a founding scientist in 1989 and led the discovery and development of seven approved drugs, including SPINRAZA® for spinal muscular atrophy (SMA) and QALSODY® for ALS.
Eric Swayze, Ph.D., will assume Bennett's responsibilities as head of research.
Bennett will serve as a strategic consultant post-retirement to support the transition.

The big picture

Frank Bennett's retirement marks the end of an era for Ionis, as he was instrumental in pioneering antisense medicines and advancing treatments for neurological diseases. His departure highlights the strategic importance of scientific leadership in biotech companies, particularly those focused on RNA-targeted therapies. Ionis must now ensure a smooth transition to maintain its competitive edge in the rapidly evolving field of genetic and neurodegenerative disease treatments.

What we're watching

Scientific Continuity: How Eric Swayze will maintain the momentum of Ionis' research pipeline, particularly in neurological diseases.
Regulatory Milestones: The pace at which zilganersen for Alexander’s disease advances through FDA review.
Pipeline Progress: Whether Ionis can sustain its track record of drug approvals under new leadership.